company background image
AMYT

Amryt Pharma NasdaqGS:AMYT Stock Report

Last Price

US$7.66

Market Cap

US$491.6m

7D

-2.7%

1Y

-28.7%

Updated

12 Aug, 2022

Data

Company Financials +
AMYT fundamental analysis
Snowflake Score
Valuation5/6
Future Growth5/6
Past Performance2/6
Financial Health2/6
Dividends0/6

AMYT Stock Overview

Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases.

Amryt Pharma plc Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Amryt Pharma
Historical stock prices
Current Share PriceUS$7.66
52 Week HighUS$12.45
52 Week LowUS$5.61
Beta0.41
1 Month Change3.24%
3 Month Change-6.70%
1 Year Change-28.74%
3 Year Changen/a
5 Year Changen/a
Change since IPO-3.65%

Recent News & Updates

Jul 14

Amryt stock rises 11% on FDA orphan drug status for Mycapssa for rare tumor condition

The U.S. Food and Drug Administration (FDA) granted orphan drug designation to Amryt's (NASDAQ:AMYT) Mycapssa to treat carcinoid syndrome (CS). CS occurs when a rare cancerous tumor called carcinoid tumor releases certain chemicals in the blood, causing several symptoms. According to the company CS is the most common functional syndrome associated with neuroendocrine tumours (NETs). Mycapssa (oral octreotide) is approved by the FDA as a long-term maintenance therapy for certain patients with acromegaly, a hormonal disorder which occurs when the pituitary gland produces too much growth hormone during adulthood. Amryt noted that its TPE platform enables the oral delivery of the octreotide molecule which is otherwise delivered as an injectable. The FDA grants orphan drug status to therapies that treat or prevent rare diseases that affect fewer than 200K people in the U.S. The designation provides certain incentives, including seven years of market exclusivity, if approved. AMYT +11.19% to $8.25 premarket July 14.

Shareholder Returns

AMYTUS PharmaceuticalsUS Market
7D-2.7%1.1%3.2%
1Y-28.7%1.3%-10.1%

Return vs Industry: AMYT underperformed the US Pharmaceuticals industry which returned 0.7% over the past year.

Return vs Market: AMYT underperformed the US Market which returned -11.7% over the past year.

Price Volatility

Is AMYT's price volatile compared to industry and market?
AMYT volatility
AMYT Average Weekly Movement5.6%
Pharmaceuticals Industry Average Movement11.7%
Market Average Movement7.7%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: AMYT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: AMYT's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2015289Joe Wileyhttps://www.amrytpharma.com

Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia. Its development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene therapy for patients with dystrophic EB.

Amryt Pharma plc Fundamentals Summary

How do Amryt Pharma's earnings and revenue compare to its market cap?
AMYT fundamental statistics
Market CapUS$491.60m
Earnings (TTM)US$2.80m
Revenue (TTM)US$239.01m

175.8x

P/E Ratio

2.1x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
AMYT income statement (TTM)
RevenueUS$239.01m
Cost of RevenueUS$116.17m
Gross ProfitUS$122.84m
Other ExpensesUS$120.05m
EarningsUS$2.80m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.044
Gross Margin51.39%
Net Profit Margin1.17%
Debt/Equity Ratio62.2%

How did AMYT perform over the long term?

See historical performance and comparison